Dear Colleagues, dear Friends,

We are facing a global pandemic with COVID-19 and our patients with thoracic malignancies are particularly susceptible. We have therefore created a global consortium, TERAVOLT (Thoracic cancERs international coVid 19 eOLlaboraTion) registry for thoracic cancers. Several other national and international societies (among them ERS, ETOP, IASLC) have already endorsed the effort.

The goal of this consortium is to gather information on patients with thoracic cancer infected with COVID-19.

We recognize there are other registries specifically for patients on checkpoint inhibitor therapy as well as other tumor types. **This registry is designed to capture patients with thoracic malignancies regardless of therapies administered.**

We aim to provide you with:

- Real-time data on therapies that are effective in treating our patients who are infected with COVID-19
- Answers to important questions identifying risk factors for developing COVID-19 and what happens to patients where therapy is delayed

We currently have more than 100 investigators from all over the world who are participating in this important initiative. We strongly encourage you to join us as well.

Every participant will be provided with a center ID for which all de-identified patient data can be entered. You will be provided also with a protocol template to obtain local IRB approval. Please note that the local IRB approval is required before any data is actually entered in the system.

We strongly hope you will consider joining us in this global effort.

Sincerely,

Marina Garassino    Leora Horn     Solange Peters
Head Thoracic Oncology  Clinical Director   Chair Medical Oncology
National Cancer Institute  Vanderbilt University Medical Center  Oncology Department – CHUV
Milan, Italy    Nashville, Tennessee, USA  Lausanne, Switzerland

Please contact Jennifer Whisenant (j.whisenant@vumc.org) to receive the protocol and initiate the process